 |
EAACI Allergopharma Award 2019 Presented at EAACI Congress 2019 in Lisbon, on 4 June 2019 to the winner, Flore Amat – MD, PhD: The awarded research project: Risk Factors For Asthma At School Age In Children With Early-Onset Atopic Dermatitis, was set out to define phenotypes of early-onset AD leading to asthma in a prospective study using an unsupervised statistical approach, using the Observatory of Risks linked with Cutaneous Atopy (ORCA) patients cohort of children aged under 12 months referred for moderate to severe AD. Results showed that,even in this specific population with early-onset AD, not all of the children follow the atopic march. Children with early-multiple sensitization have the highest risk of sensitization to aeroallergens and asthma at school-age. These results from this patients cohort need to be independently validated, and are about to be replicated in two Europeans birth cohorts, MAS and PIAMA. |
 |
EAACI Allergopharma Award 2018 Presented at EAACI Congress 2018 in Munich, on 26 May 2018 to the winner, Brecht Steelant - PhD, Postdoctoral Researcher. The awarded research project “Regulation Of Epithelial Barrier Function In Allergic Rhinitis”, will be carried out for one year at the Laboratory of Clinical Immunology, in Leuven, Belgium. Purpose of the study: Purpose of the study was to unravel the role of epithelial barrier function in allergic rhinitis and how it contributes to disease severity and chronicity. By studying epithelial integrity and tight junction expression, we aim at discovering novel therapeutic approaches in the treatment of allergic rhinitis. |
 |
EAACI Allergopharma Award 2017 Presented at EAACI Congress 2017 in Helsinki, on 17 June 2017 to the winner, Kristina Britt Charlotte Johansson, MSc, PhD candidate: The awarded research project “MicroRNA regulation in asthma”, was carried out for one year at Krefting Research Centre at the University of Gothenburg in Gothenburg, Sweden. Purpose of the study: MicroRNAs regulate cellular pathways and are required for normal cell behavior. By studying microRNA expression under inflammatory settings in humans and mice we aim to uncover novel genes and pathways that are critical to asthma pathology. |
 |
EAACI Allergopharma Award 2016 Presented at EAACI in Vienna, the 11th of June 2016 to the winner, Dr. Irisz Karolina Levai: The awarded research project “Continuous laryngoscopy during exercise and assessment of parasympathetic activity in patients with exercise-induced laryngeal obstruction (EILO)”, was carried out for 6 months at Haukeland University Hospital (HUS) in Bergen (Norway). The purpose of this study was to address potential effects from Atrovent in patients with exercise-induced laryngeal obstruction (EILO) verified during a continuous laryngoscopy exercise (CLE) test. |
 |
EAACI Allergopharma Award 2015 Presented at EAACI in Barcelona, the 7th of June 2015 to the winner, Dr. Alexander Eggel, based on the article Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. Eggel et al, J Allergy Clin Immunol, 2014, Vol. 133, No. 6. Dr. Eggel obtained his PhD degree at University of Bern in Switzerland and following a year as Postdoctoral Fellow at the University of Stanford, he returned to Bern and is currently Group Leader at the Institute of Immunology. Over the years, he has received several recognitions for outstanding work in the fields of allergy and immunology. In several publications the focus of has been on IgE/IgE-receptor interactions. The awarded publication describes the action of a new class of IgE inhibitors with therapeutic potential acting by suppression of the allergic response of effector cells from sensitised individuals.Thereby this paper provides new knowledge as well as points at potential applications in present and future diagnostic and therapeutic regimens. |